Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
EDISON EQUITY RESEARCH: BAVARIAN NORDIC – ADR OUTLOOK The BMS and J&J deals, and continued Imvamune related income have provided Bavarian Nordic with validation of its vaccine...
Bavarian Nordic to receive up to $975 million, inclusive of $60 million upfront and potential exercise payment; potential development, regulatory and commercialization milestone payments;...
EDISON EQUITY RESEARCH: BAVARIAN NORDIC - STRATEGIC EBOLDA DEAL FILLS 2015 REVENUE GAP Bavarian Nordic’s $187m exclusive global licensing and supply deal for its development Ebola vaccine...
KVISTGAARD, Denmark, July 24, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that the first patient has been treated in an NCI-sponsored Phase 1 study of...
KVISTGAARD, Denmark, May 28, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that Paul Chaplin, Ph.D. has been appointed new President and CEO of the Company...
KVISTGAARD, Denmark, May 15, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today two papers featuring the combination of the Company's proprietary cancer...
KVISTGAARD, Denmark, May 14, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first quarter of 2014. Revenue...
KVISTGAARD, Denmark, April 28, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the first patient has now been treated in a randomized, prospective Phase 2...
KVISTGAARD, Denmark, March 19, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) today published its 2013 annual report. Revenue was DKK 1,213 million / USD 224 million (DKK...
Alliance For Biosecurity Elects Chief Executive Officers Of Bavarian Nordic And Elusys Therapeutics As New Co-Chairs Leadership Team Will Advance Industry Efforts Supporting the Development of...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.31 | -3.4140969163 | 9.08 | 9.23 | 8.76 | 5484 | 8.95094039 | DR |
| 4 | -0.39 | -4.2576419214 | 9.16 | 9.39 | 8.34 | 9282 | 9.0148518 | DR |
| 12 | -1.868 | -17.5596916714 | 10.638 | 10.8375 | 7.89 | 22854 | 9.18992954 | DR |
| 26 | 0.192 | 2.23828398228 | 8.578 | 15.11 | 7.89 | 56844 | 12.10320365 | DR |
| 52 | 0.835 | 10.5229993699 | 7.935 | 15.11 | 6.86 | 32144 | 11.77979004 | DR |
| 156 | -2.63 | -23.0701754386 | 11.4 | 20.67 | 5.85 | 47193 | 13.22956701 | DR |
| 260 | -0.54 | -5.80021482277 | 9.31 | 20.67 | 5.04 | 37945 | 13.22662807 | DR |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
